Form 4: United Therapeutics Exec Trades Shares Under 10b5-1 Plan

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported significant stock transactions on April 2, 2026, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., engaged in a series of stock transactions on April 2, 2026.
• These transactions involved the exercise of stock options and the subsequent sale of common stock.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on November 7, 2025.
• The 10b5-1 plan is set to continue until the exercise of 1,734,410 stock options (expiring March 17, 2027) or December 31, 2026, whichever comes first.
• Rothblatt acquired 9,500 shares via option exercise at a price of $146.03 per share.
• Subsequently, a total of 49,948 shares were disposed of through various sales at weighted average prices ranging from $552.2469 to $571.6633.
• Following these transactions, Rothblatt beneficially owns 40,513 shares directly, with additional holdings through a spouse, and various trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it details routine insider transactions executed under a pre-established plan, which mitigates concerns about opportunistic selling.

Positives

• The exercise and sale of shares were conducted under a pre-arranged 10b5-1 trading plan, indicating a structured and compliant approach to managing personal stock holdings.
• The plan allows for continued transactions until specific option exercise targets or a set date, suggesting ongoing management of equity.
• The weighted average sale prices indicate a strong market value for the company's common stock during the transaction period.

Negatives

• A significant number of shares were sold, which could be interpreted negatively by the market if not contextualized by the 10b5-1 plan.
• The total number of shares disposed of through sales is substantial, representing a considerable reduction in direct holdings by a key executive.

Risks

• The ongoing 10b5-1 plan has an expiration date of December 31, 2026, or upon exercise of all remaining options, introducing a time-bound element to future transactions.
• The plan's continuation is also contingent on the exercise of 1,734,410 stock options, which expire on March 17, 2027.

Future Outlook

The 10b5-1 trading plan is active and will continue until December 31, 2026, or until 1,734,410 stock options are exercised, whichever occurs first. The plan governs the exercise of stock options and the sale of resulting common stock.

Management Comments

• The exercise of stock options and sale of resulting shares were pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected for multiple transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions are common for publicly traded companies. The use of a 10b5-1 plan by a CEO like Martine Rothblatt at United Therapeutics is a standard practice for executives to manage their stock portfolios in a way that avoids the appearance of insider trading, especially when significant option expirations or planned sales are involved.

Stakeholder Impact

• Shareholders may observe the significant sale of shares by a key executive, though the 10b5-1 plan context should temper concerns about insider selling.
• The transactions reflect the executive's management of personal equity, which is a standard aspect of corporate governance.

Next Steps

• The 10b5-1 trading plan will continue until December 31, 2026, or until 1,734,410 stock options are exercised.
• Further transactions may occur under the plan as options are exercised and shares are sold.

Key Dates

Keywords

Form 4, SEC Filing, United Therapeutics, UTHR, Martine Rothblatt, Stock Options, 10b5-1 Plan, Insider Trading, Beneficial Ownership, Common Stock, Shareholder